Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.32 |
| ▸ | CDK9 | P50750 | 6/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 3/20 | 0.32 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15415732 | 0.94 | ALKBH1 (0.36) | ALKBH1SLC2A1IGF1RTNFEPHB3 | |
| SCHEMBL16909715 | 0.93 | ALKBH1 (0.35) | ALKBH1SLC2A1CCNT1CDK9TNF | |
| SCHEMBL16909817 | 0.92 | ALKBH1 (0.36) | ALKBH1PTPN11SLC2A1CCNT1CDK9 | |
| SCHEMBL16909705 | 0.86 | TNF (0.34) | ALKBH1SLC2A1TNFEPHB3RIPK1 | |
| SCHEMBL16909426 | 0.85 | ALKBH1 (0.38) | ALKBH1SLC2A1TNFEPHB3 | |
| SCHEMBL16909689 | 0.84 | ALKBH1 (0.34) | ALKBH1SLC2A1IGF1RTNFEPHB3 | |
| SCHEMBL16909556 | 0.84 | ALKBH1 (0.38) | ALKBH1SLC2A1IGF1RTNFEPHB3 | |
| SCHEMBL16909815 | 0.84 | ALKBH1 (0.38) | ALKBH1SLC2A1IGF1RTNFEPHB3 | |
| SCHEMBL16909558 | 0.84 | ALKBH1 (0.38) | ALKBH1SLC2A1IGF1RTNFEPHB3 | |
| SCHEMBL16874416 | 0.84 | CDK9 (0.35) | ALKBH1CCNT1CDK9IGF1RTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | claimed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | ALKBH1 4341/4885PTPN11 789/4885SLC2A1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.